En español
NIDA

Methadone

Gene Variants Reduce Opioid Risks

Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.

Dr. Evan D. Kharasch Joins the Institute of Medicine

Dr. Kharasch is a NIDA-funded researcher known for a broad range of research into how drugs are metabolized in the body.

Medications That Treat Opioid Addiction Do Not Impair Liver Health

A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.

Dr. Marilyn Huestis Q & A: Matching Drug Effects to Drug Concentrations

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

Q & A: Dr. Redonna Chandler

The chief of NIDA's Services Research Branch talks about drug abuse treatment within the criminal justice system, and assesses the challenges facing drug abuse treatment overall in the United States.

Crime Does Not Increase Around Methadone Clinics in Baltimore

Methadone treatment centers are not foci for serious criminal activity, according to a study that used crime reports and global positioning data to compare crime rates at various distances around methadone centers, hospitals, convenience stores, and residential neighborhoods.

Buprenorphine During Pregnancy Reduces Neonate Distress

Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.

Medical Care During Addiction Treatment Reduces Hospital Use

Reports on an analysis comparing three types of addiction treatment programs: methadone maintenance programs, long-term residential programs, and nonmethadone programs.

Interim Methadone Raises Odds of Enrolling in Comprehensive Treatment

Reports on a study to investigate the use of methadone maintenance for heroin addicts wait-listed for a treatment program to encourage their likelihood to enroll in the program.

Pages

Subscribe to Methadone